Novartis Extends Triaminic Into Brand Name Void Left By J&J Tylenol Recall
This article was originally published in The Tan Sheet
Executive Summary
Novartis expedites a Triaminic line extension to take advantage of the branded product gap left by the recall of Johnson & Johnson's Children's Tylenol liquid OTCs